Dubinsky MC - Search Results

1

A pilot study of adalimumab in infliximab-allergic patients.

Youdim A, Vasiliauskas EA, Targan SR, Papadakis KA, Ippoliti A, Dubinsky MC, Lechago J, Paavola J, Loane J, Lee SK, Gaiennie J, Smith K, Do J, Abreu MT. Youdim A, et al. Among authors: dubinsky mc. Inflamm Bowel Dis. 2004 Jul;10(4):333-8. doi: 10.1097/00054725-200407000-00002. Inflamm Bowel Dis. 2004. PMID: 15475739 Clinical Trial.

2

Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease.

Ruemmele FM, Targan SR, Levy G, Dubinsky M, Braun J, Seidman EG. Ruemmele FM, et al. Gastroenterology. 1998 Oct;115(4):822-9. doi: 10.1016/s0016-5085(98)70252-5. Gastroenterology. 1998. PMID: 9753483

3

Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease.

Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Théorêt Y, Seidman EG. Dubinsky MC, et al. Gastroenterology. 2000 Apr;118(4):705-13. doi: 10.1016/s0016-5085(00)70140-5. Gastroenterology. 2000. PMID: 10734022 Clinical Trial.

4

An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy.

Dubinsky MC, Hassard PV, Seidman EG, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA. Dubinsky MC, et al. Inflamm Bowel Dis. 2001 Aug;7(3):181-9. doi: 10.1097/00054725-200108000-00001. Inflamm Bowel Dis. 2001. PMID: 11515842 Clinical Trial.

5

6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease.

Dubinsky MC, Yang H, Hassard PV, Seidman EG, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA. Dubinsky MC, et al. Gastroenterology. 2002 Apr;122(4):904-15. doi: 10.1053/gast.2002.32420. Gastroenterology. 2002. PMID: 11910342 Clinical Trial.

6

Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine.

Dubinsky MC, Feldman EJ, Abreu MT, Targan SR, Vasiliauskas EA. Dubinsky MC, et al. Am J Gastroenterol. 2003 May;98(5):1058-63. doi: 10.1111/j.1572-0241.2003.07413.x. Am J Gastroenterol. 2003. PMID: 12809828

7

6-thioguanine can cause serious liver injury in inflammatory bowel disease patients.

Dubinsky MC, Vasiliauskas EA, Singh H, Abreu MT, Papadakis KA, Tran T, Martin P, Vierling JM, Geller SA, Targan SR, Poordad FF. Dubinsky MC, et al. Gastroenterology. 2003 Aug;125(2):298-303. doi: 10.1016/s0016-5085(03)00938-7. Gastroenterology. 2003. PMID: 12891528

8

Monitoring of AZA/6-MP treatment in children with IBD is necessary.

Dubinsky MC. Dubinsky MC. Inflamm Bowel Dis. 2003 Nov;9(6):386-8; discussion 392-3. doi: 10.1097/00054725-200311000-00007. Inflamm Bowel Dis. 2003. PMID: 14671488 No abstract available.

9

Early nodular hyperplasia of the liver occurring with inflammatory bowel diseases in association with thioguanine therapy.

Shastri S, Dubinsky MC, Fred Poordad F, Vasiliauskas EA, Geller SA. Shastri S, et al. Among authors: dubinsky mc. Arch Pathol Lab Med. 2004 Jan;128(1):49-53. doi: 10.5858/2004-128-49-ENHOTL. Arch Pathol Lab Med. 2004. PMID: 14692812 Free article.

10

Initial experience with wireless capsule enteroscopy in the diagnosis and management of inflammatory bowel disease.

Mow WS, Lo SK, Targan SR, Dubinsky MC, Treyzon L, Abreu-Martin MT, Papadakis KA, Vasiliauskas EA. Mow WS, et al. Among authors: dubinsky mc. Clin Gastroenterol Hepatol. 2004 Jan;2(1):31-40. doi: 10.1016/s1542-3565(03)00289-1. Clin Gastroenterol Hepatol. 2004. PMID: 15017630

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

403 results

Search Page

Filters